Kaitlyn D’Onofrio

DocwireNews

Although oral fingolimod is more convenient than injectable disease-modifying agents (DMAs) in patients with multiple sclerosis (MS), it is unclear which option has a better adherence trajectory. According to a retrospective, longitudinal study comparing the two treatment options, oral fingolimod was correlated with better adherence.Patients with MS aged &ge;18 years were identified in the IBM MarketScan Commercial Claims and Encounters Database between 2010 and 2012 by ICD-9-CM: 340 had a DMA prescription. Eligible patients were stratified by whether they received oral fingolimod or injectable DMA per the index DMA. Annual DMA adherence trajectories were determined using the proportion of days covered (PDC), which was evaluated by using group-based trajectory modeling (GBTM) over the one-year period following treatment initiation. The relationship between the DMA route of administration and the adherence trajectory groups was analyzed by conducting multivariable multinomial logistic regression using stabilized inverse probability treatment weights (IPTW). A standardized difference threshold of 0.25 was used to balance covariates between the groups before and after IPTW.A total of 1,700 patients with MS constituted the study group; most patients had initiated injectable DMAs (84.2%). The adherence rate (PDC &ge;0.8) was higher in the oral group than the injectable group (64.7% vs. 50.8%). Using GBTM, patients were stratified into three adherence groups: rapid discontinuers (23.5%), complete adherers (49.9%), and slow decliners (26.6%). When the multinomial logistic regression model with stabilized IPTW was implemented, oral fingolimod users, compared with injectable DMA users, had greater odds of being a complete adherer (adjusted odds ratio [aOR], 2.78; 95% confidence interval [CI], 1.85-4.16) or slow discontinuer (aOR, 2.62; 95% CI, 1.70-4.05).&ldquo;Further research is warranted to evaluate the adherence trajectories with newer oral DMAs introduced in the last decade for MS,&rdquo; the study authors concluded.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Oral Versus Injectable Disease-Modifying Agents: Which Has Better Adherence?

Multiple Sclerosis

Although oral fingolimod is more convenient than injectable disease-modifying agents (DMAs) in patients with multiple sclerosis (MS), it is unclear which option has a better ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe